| Efficacy and safety of mirikizumab in a randomized phase 2 study of patients with ulcerative colitis WJ Sandborn, M Ferrante, BR Bhandari, E Berliba, BG Feagan, T Hibi, ... Gastroenterology 158 (3), 537-549. e10, 2020 | 180 | 2020 |
| Efficacy and safety of continued treatment with mirikizumab in a phase 2 trial of patients with ulcerative colitis WJ Sandborn, M Ferrante, BR Bhandari, E Berliba, T Hibi, GR D’Haens, ... Clinical Gastroenterology and Hepatology 20 (1), 105-115. e14, 2022 | 40 | 2022 |
| Safety, pharmacokinetics, and antiviral activity of AT-527, a novel purine nucleotide prodrug, in hepatitis C virus-infected subjects with or without cirrhosis E Berliba, M Bogus, F Vanhoutte, PJ Berghmans, SS Good, A Moussa, ... Antimicrobial agents and chemotherapy 63 (12), 10.1128/aac. 01201-19, 2019 | 38 | 2019 |
| 882-Efficacy and safety of anti-interleukin-23 therapy with mirikizumab (Ly3074828) in patients with moderate-to-severe ulcerative colitis in a phase 2 study WJ Sandborn, M Ferrante, BR Bhandari, GR D'Haens, E Berliba, ... Gastroenterology 154 (6), S-1360-S-1361, 2018 | 34 | 2018 |
| Safety and pharmacodynamics of the GalNAc-siRNA AB-729 in subjects with chronic hepatitis B infection RMF Yuen, E Berliba, YJ Kim, JA Holmes, YS Lim, SI Strasser, ... The Annual Meeting of the American Association for the Study of Liver …, 2020 | 19 | 2020 |
| Repeat dosing of the GalNAc-siRNA AB-729 in subjects with chronic hepatitis B results in robust and sustained HBsAg suppression RMF Yuen, E Berliba, W Sukeepaisarnjaroen, S Strasser, P Tangkijvanich, ... The International Liver Congress 2021 (ILC 2021), 2021 | 15 | 2021 |
| AT-527, a pan-genotypic purine nucleotide prodrug, exhibits potent antiviral activity in subjects with chronic hepatitis C X Zhou, E Berliba, F Vanhoutte, M Bogus, PJ Berghmans, K Pietropaolo, ... International Liver Congress, 2018 | 12 | 2018 |
| Safety, pharmacokinetics, and antiviral activity of the capsid inhibitor AB‐506 from Phase 1 studies in healthy subjects and those with hepatitis B MF Yuen, E Berliba, W Sukeepaisarnjaroen, SH Ahn, T Tanwandee, ... Hepatology Communications 6 (12), 3457-3472, 2022 | 11 | 2022 |
| A phase 1a study of AT-527, a novel pan-genotypic purine nucleotide prodrug inhibitor of hepatitis C virus (HCV) XJ Zhou, F Vanhoutte, E Berliba, PJ Berghmans, M Bogus, SS Good, ... Headache 2 (2), 3, 2017 | 11 | 2017 |
| AL-335, a once-daily pangenotypic nucleotide HCV polymerase inhibitor, demonstrates potent antiviral activity over 7 days in treatment-naïve genotype 1-4 patients E Berliba, T Tsertsvadze, N Ghicavii, D Guyader, T Kakabadze, ... Journal of Hepatology 64 (2), S404-S405, 2016 | 11 | 2016 |
| OP38 Maintenance treatment with mirikizumab, a p19-directed IL-23 antibody: 52-week results in patients with moderately-to-severely active ulcerative colitis GGR D’Haens, WJ Sandborn, M Ferrante, BR Bhandari, E Berliba, T Hibi, ... Journal of Crohn's and Colitis 13 (Supplement_1), S026-S027, 2019 | 10 | 2019 |
| Safety, tolerability, and pharmacokinetics of AL-335 in healthy volunteers and hepatitis C virus-infected subjects MW McClure, E Berliba, T Tsertsvadze, A Streinu-Cercel, L Vijgen, ... Plos one 13 (10), e0204974, 2018 | 10 | 2018 |
| Long-term suppression maintained after cessation of AB-729 treatment and comparable on-treatment response observed in HBeAg+ subjects MF Yuen, E Berliba, W Sukeepaisarnjaroen, J Holmes, A Leerapun, ... Journal of Hepatology 77, S876-S877, 2022 | 8 | 2022 |
| Safety, antiviral activity and pharmacokinetics of JNJ-64530440, a novel capsid assembly modulator, as 4 week monotherapy in treatment-naive patients with chronic hepatitis B … EJ Gane, C Schwabe, E Berliba, P Tangkijvanich, A Jucov, N Ghicavii, ... Journal of Antimicrobial Chemotherapy 77 (4), 1102-1110, 2022 | 8 | 2022 |
| A combination of AT-527, a pan-genotypic guanosine nucleotide prodrug, and daclatasvir was well-tolerated and effective in HCV-infected subjects E Berliba, A Jucov, SS Good, A Moussa, K Pietropaolo, X Zhou, ... Journal of Hepatology, 2020 | 8 | 2020 |
| Safety, tolerability, pharmacokinetics (PK), and antiviral activity of the capsid inhibitor (CI) AB-506 in healthy subjects (HS) and chronic hepatitis B (CHB) subjects RMF Yuen, E Berliba, W Sukeepaisarnjaroen, SH Ahn, T Tanwandee, ... The 70th Annual Meeting of the American Association for the Study of Liver …, 2019 | 7 | 2019 |
| Lupaşco Iu. Ficatul şi alcoolul V Dumbrava, E Berliba Monografie. Chişinău 298, 2008 | 7 | 2008 |
| Low HBsAg levels maintained following cessation of the GALNAC-siRNA, AB-729, in chronic hepatitis B subjects on nucleos (T) IDE analogue therapy MF Yuen, E Berliba, W Sukeepaisarnjaroen, P Tangkijvanich, A Leerapun, ... Hepatology 74 (6), 1402A-1403A, 2021 | 6 | 2021 |
| VX-135, a once-daily nucleotide HCV polymerase inhibitor, was well tolerated and demonstrated potent antiviral activity when given with ribavirin in treatment-naïve patients … S Popa, A Berliba, N Ghicavii, AA Patat, RS Kauffman, J Krop, V Garg, ... Hepatology 58, 745A, 2013 | 6 | 2013 |
| Scorurile prognostice a riscului de mortalitate la pacienții din lista de așteptare pentru transplantul hepatic V Spinei, E Tcaciuc, E Berliba, A Ţurcanu, N Taran, G Ivancov, ... Buletinul Academiei de Ştiinţe a Moldovei. Ştiinţe Medicale 62 (2), 135-141, 2019 | 4 | 2019 |
